SC
ZNTL icon

Savant Capital’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Savant Capital’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-23,893
Closed -$72.4K – 1458
2024
Q4 		$72.4K Buy
+23,893
New +$78.3K ﹤0.01% 1395

Other funds holding ZNTL

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Savant Capital's ZNTL Position: Q1 2025 in Review

Savant Capital sold out of Zentalis Pharmaceuticals (ZNTL) in Q1 2025, closing a stake of 23,893 shares — an estimated $72.4K sold.

Savant Capital first reported a position in ZNTL in Q4 2024 and held it in 1 quarter. The position peaked at $72.4K in Q4 2024. 132 funds tracked by Wall St. Rank hold ZNTL as of Q1 2025.

  • Savant Capital reported no remaining Zentalis Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Savant Capital sold 23,893 Zentalis Pharmaceuticals shares in Q1 2025, an estimated $72.4K.
  • Savant Capital first reported a position in Zentalis Pharmaceuticals in Q4 2024 and held it in 1 quarter.
  • Savant Capital's Zentalis Pharmaceuticals position peaked at $72.4K in Q4 2024.
  • 132 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q1 2025.

Based on Savant Capital's 13F filing for Q1 2025, filed 8 May 2025.